Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026